The National Institute for Food and Drug Surveillance (INVIMA) has announced a comprehensive strategy to address a significant backlog of requests for medicines and biological products. The causes identified include delays in previous terms, cybersecurity attacks, modernization needs in the technological infrastructure and the expansion of budgetary capacities. As of April 2023, 27,904 requests with delays were registered, of which 26,049 date from 2016 to November 2023. To address this problem, INVIMA has outlined a short, medium and long-term work plan, with the aim of resolving 85% of the accumulated requests by June 2024, addressing medicines that are out of stock, at risk of supply and under monitoring.
This approach seeks to optimize INVIMA's efficiency and response capacity in the face of challenges that have affected the regular flow of approvals and procedures for pharmaceutical products in the country, thus helping to ensure the timely and safe supply of essential medicines.
Conoce cuáles son las estrategias y cómo impactan en su gestión para mejorar el acceso a medicamentos esenciales, leyendo completa nuestra noticia en Gaffel News.
Source: Consultor Salud